RESUMEN
Necrotising enterocolitis (NEC) is the most common acquired gastrointestinal emergency in neonates. Presence of pneumatosis intestinalis is taken as evidence of definite NEC. A distinctive but rare form of NEC called "pneumatosis coli" has been described, presenting with gross blood in stools and minimal or absent local and systemic signs. Radio-graph characteristically reveal isolated colonic pneumatosis without small bowel involvement. Pneumatosis coli has a more benign course compared with definite NEC. Total parenteral nutrition, antibiotics, an appropriate duration off feeds and close observation remain the corner stones of therapy assuring a benign course.
Asunto(s)
Enfermedades del Colon/diagnóstico , Enterocolitis Necrotizante/diagnóstico , Humanos , Recién Nacido , Enfermedades del Prematuro/diagnóstico , Masculino , Neumatosis Cistoide Intestinal/diagnóstico , PronósticoAsunto(s)
Anomalías Múltiples/diagnóstico , Adolescente , Puntaje de Apgar , Córnea/anomalías , Anomalías Craneofaciales/diagnóstico , Oído/anomalías , Resultado Fatal , Femenino , Edad Gestacional , Deformidades de la Mano/diagnóstico , Hernia Diafragmática/diagnóstico , Humanos , Recién Nacido , Masculino , Cuello/anomalías , Nariz/anomalías , Embarazo , Resultado del Embarazo , Síndrome , Ultrasonografía Prenatal/métodosAsunto(s)
Cefotaxima/uso terapéutico , Infección Hospitalaria/tratamiento farmacológico , Quimioterapia Combinada/uso terapéutico , Femenino , Humanos , Recién Nacido , Recien Nacido Prematuro , Sepsis/tratamiento farmacológico , Infecciones Estafilocócicas/microbiología , Vancomicina/uso terapéuticoAsunto(s)
Benzotiadiazinas , Broncodilatadores/efectos adversos , Enfermedades en Gemelos , Diuréticos , Humanos , Hiponatremia/inducido químicamente , Síndrome de Secreción Inadecuada de ADH/inducido químicamente , Recién Nacido , Respiración Artificial , Síndrome de Dificultad Respiratoria del Recién Nacido/tratamiento farmacológico , Inhibidores de los Simportadores del Cloruro de Sodio/efectos adversos , Teofilina/efectos adversosAsunto(s)
Adulto , Bacteriemia/diagnóstico , Infección Hospitalaria/diagnóstico , Países en Desarrollo , Femenino , Humanos , India , Recién Nacido , Enfermedades del Prematuro/diagnóstico , Masculino , Embarazo , Embarazo de Alto Riesgo , Embarazo Múltiple , Pseudomonas/patogenicidad , Infecciones por Pseudomonas/diagnóstico , Trillizos , VirulenciaRESUMEN
OBJECTIVE: To evaluate safety and efficacy of recombinant human erythropoietin (r-HuEPO)in reducing the need for red cell transfusions in anemia of prematurity. METHODS: forty -two preterm infants (gestational age <32 weeks) were randomly assigned to a "treatment" group (r-HuEPO 400 units/kg every alternate day * 10 doses) or "no treatment" (control) group. All infants on enteral feeds received oral iron 3 mg/kg/day, graded up to 6 mg/kg/day. RESULTS: Higher reticulocyte counts in week 2 and 3 and higher hemoglobin levels in week 4 were noted after treatment with r-HuEPO. Despite stumulated erythropoiesis, the frequency of transfusions could not be reduced with r-HuEPO therapy.Overall, Phlebotomy losses, frequency and volume of redcell transfusions were significantly more in neonates with birthweight <1000 grams compared with those with birthweight >1000 grams (p<0.05). Associated side effects of r-HuEPO such as neutropenia,sepsis, hypertension or increased risk of late death did not occur. CONCLUSION:r-HuEPO therapy was safe without any side effects.Inability of r-HuEPO therapy to minimize red cell transfusions for anemia of prematurity may be explained by a relatively strict red-cell transfusion policy and the desired degree of treatment effect.